Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: Effect of acyl chain length

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Cmielewski, Patricia ^a,b   Anson, Don S ^a   Parsons, David W ^a,b,c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Women's and Children's Health Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DECANOYL; HEPTADECANOYL; IMMUNOLOGICAL ADJUVANT; LAUROYL; LENTIVIRUS VECTOR; LIPID; LYSOPHOSPHATIDYLCHOLINE; MYRISTOYL; OLEOYL; PALMITOYL; STEAROYL; UNCLASSIFIED DRUG; SURFACTANT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DISRUPTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DEPOLARIZATION; ELECTROPHYSIOLOGY; FEMALE; GENETIC TRANSDUCTION; HISTOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; POTENTIAL DIFFERENCE; PSEUDOTYPING; RESPIRATORY EPITHELIUM; TIGHT JUNCTION; TRANSEPITHELIAL DEPOLARIZATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; ANIMAL; C57BL MOUSE; CELL MEMBRANE POTENTIAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENE VECTOR; GENETICS; INTRANASAL DRUG ADMINISTRATION; LACTOSE OPERON; LENTIVIRINAE; METABOLISM; METHODOLOGY; NOSE MUCOSA; PERMEABILITY; TIME;

ADMINISTRATION, INTRANASAL; ANIMALS; FEMALE; GENETIC VECTORS; LAC OPERON; LENTIVIRUS; LYSOPHOSPHATIDYLCHOLINES; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; NASAL MUCOSA; PERMEABILITY; SURFACE-ACTIVE AGENTS; TIGHT JUNCTIONS; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 77956667210     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-84     Document Type: Article

References (34)

1. Rosenecker J, Huth S, Rudolph C. Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr Opin Mol Ther 2006, 8:439-445.
2. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006, 13:1061-1067. 10.1038/sj.gt.3302809, 16819538.
3. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002, 54:1373-1393. 10.1016/S0169-409X(02)00145-X, 12458150.
4. Pickles RJ. Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thorac Soc 2004, 1:302-308. 10.1513/pats.200403-024MS, 16113450.
5. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004, 15:1157-1166. 10.1089/hum.2004.15.1157, 15684693.
6. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6:1574-1583. 10.1038/sj.gt.3300994, 10490767.
7. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J, Moscicki RA, Richards SM, Standaert TA, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996, 97:1504-1511. 10.1172/JCI118573, 507211, 8617884.
8. Koehler DR, Martin B, Corey M, Palmer D, Ng P, Tanswell AK, Hu J. Readministration of helper-dependent adenovirus to mouse lung. Gene Ther 2006, 13:773-780. 10.1038/sj.gt.3302712, 16437131.
9. Koehler DR, Frndova H, Leung K, Louca E, Palmer D, Ng P, McKerlie C, Cox P, Coates AL, Hu J. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med 2005, 7:1409-1420. 10.1002/jgm.797, 15999396.
10. Hiatt P, Brunetti-Pierri N, Koehler D, McConnell R, Katkin J, Palmer D, Dimmock D, Hu J, Finegold M, et al. Aerosol delivery of helper-dependent adenoviral vector into nonhuman primate lungs results in high efficiency pulmonary transduction with minimal toxicity. Molecular Therapy 2005, 11:S317.
11. Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002, 13:1961-1970. 10.1089/10430340260355365, 12427306.
12. Stocker AG, Kremer KL, Koldej R, Miller DS, Anson DS, Parsons DW. Single-dose lentiviral gene transfer for lifetime airway gene expression. J Gene Med 2009, 11:861-867. 10.1002/jgm.1368, 19634193.
13. Kremer KL, Dunning KR, Parsons DW, Anson DS. Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors. J Gene Med 2007, 9:362-368. 10.1002/jgm.1025, 17380490.
14. Mery S, Gross EA, Joyner DR, Godo M, Morgan KT. Nasal diagrams: a tool for recording the distribution of nasal lesions in rats and mice. Toxicol Pathol 1994, 22:353-372. 10.1177/019262339402200402, 7817125.
15. Sugiura T, Kudo N, Ojima T, Mabuchi-Itoh K, Yamashita A, Waku K. Coenzyme A-dependent cleavage of membrane phospholipids in several rat tissues: ATP-independent acyl-CoA synthesis and the generation of lysophospholipids. Biochim Biophys Acta 1995, 1255:167-176.
16. Post M, Batenburg JJ, Schuurmans EA, Laros CD, van Golde LM. Lamellar bodies isolated from adult human lung tissue. Exp Lung Res 1982, 3:17-28. 10.3109/01902148209115812, 6895870.
17. Bernhard W, Postle AD, Linck M, Sewing KF. Composition of phospholipid classes and phosphatidylcholine molecular species of gastric mucosa and mucus. Biochim Biophys Acta 1995, 1255:99-104.
18. Griesenbach U, Smith SN, Farley R, Singh C, Alton EW. Validation of nasal potential difference measurements in gut-corrected CF knockout mice. Am J Respir Cell Mol Biol 2008, 39:490-496. 10.1165/rcmb.2007-0385OC, 18458238.
19. Chandler SG, Thomas NW, Illum L. Nasal absorption in the rat. III. Effect of lysophospholipids on insulin absorption and nasal histology. Pharm Res 1994, 11:1623-1630. 10.1023/A:1018970006935, 7870681.
20. Griesenbach U, Alton EW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009, 61:128-139. 10.1016/j.addr.2008.09.010, 19138713.
21. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000, 74:3852-3858. 10.1128/JVI.74.8.3852-3858.2000, 111893, 10729159.
22. Pickles RJ, Fahrner JA, Petrella JM, Boucher RC, Bergelson JM. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol 2000, 74:6050-6057. 10.1128/JVI.74.13.6050-6057.2000, 112103, 10846088.
23. Marttin E, Schipper NG, Verhoef JC, Merkus FW. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998, 29:13-38. 10.1016/S0169-409X(97)00059-8, 10837578.
24. Stonebraker JR, Wagner D, Lefensty RW, Burns K, Gendler SJ, Bergelson JM, Boucher RC, O'Neal WK, Pickles RJ. Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to lumenal infection. J Virol 2004, 78:13755-13768. 10.1128/JVI.78.24.13755-13768.2004, 533903, 15564484.
25. Mitomo K, Griesenbach U, Inoue M, Somerton L, Meng C, Akiba E, Tabata T, Ueda Y, Frankel GM, Farley R, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 2010, 18:1173-1182. 10.1038/mt.2010.13, 20332767.
26. Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 2005, 79:12818-12827. 10.1128/JVI.79.20.12818-12827.2005, 1235842, 16188984.
27. Rock JR, Onaitis MW, Rawlins EL, Lu Y, Clark CP, Xue Y, Randell SH, Hogan BL. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc Natl Acad Sci USA 2009, 106:12771-12775. 10.1073/pnas.0906850106, 2714281, 19625615.
28. Ojala PJ, Hirvonen TE, Hermansson M, Somerharju P, Parkkinen J. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J Leukoc Biol 2007, 82:1501-1509. 10.1189/jlb.0507292, 17884992.
29. Kim YL, Im YJ, Ha NC, Im DS. Albumin inhibits cytotoxic activity of lysophosphatidylcholine by direct binding. Prostaglandins Other Lipid Mediat 2007, 83:130-138. 10.1016/j.prostaglandins.2006.10.006, 17259079.
30. Ginsburg I, Ward PA, Varani J. Lysophosphatides enhance superoxide responses of stimulated human neutrophils. Inflammation 1989, 13:163-174. 10.1007/BF00924787, 2547711.
31. Dannhoffer L, Blouquit-Laye S, Regnier A, Chinet T. Functional properties of mixed cystic fibrosis and normal bronchial epithelial cell cultures. Am J Respir Cell Mol Biol 2009, 40:717-723. 10.1165/rcmb.2008-0018OC, 19011164.
32. Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, Dang YL, Vogel LN, McKay T, Mengos A, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009, 7:e1000155. 10.1371/journal.pbio.1000155, 2705187, 19621064.
33. Wang G, Slepushkin V, Zabner J, Keshavjee S, Johnston JC, Sauter SL, Jolly DJ, Dubensky TW, Davidson BL, McCray PB. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest 1999, 104:R55-62. 10.1172/JCI8390, 483477, 10587528.
34. Erjefalt JS, Persson CG. Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. Thorax 1997, 52:1010-1012. 10.1136/thx.52.11.1010, 1758444, 9487352.